NAFLD is associated with decreased hepatic expression of the two adiponectin receptors (AdipoR1 and 2), thereby contributing to a state of hepatic adiponectin resistance [33]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.